Refine Results
  1. "Clifford Hudis"
Formats
  1. Journal Article (478)
  2. Meeting Abstract (393)
  3. Book Section (15)
  4. Conference Paper (10)
  5. Book Whole (2)
Groups
  1. Breast Medicine Service (898)
  2. Solid Tumor Oncology Division (898)
  3. Survivorship Research (898)
  4. Breast Cancer Disease Management Team (472)
  5. Epidemiology and Biostatistics (229)
  6. Biostatistics Service (220)

More Groups

People
  1. Clifford Hudis (898)
  2. Larry Norton (292)
  3. Sujata Patil (141)
  4. Andrew Seidman (116)
  5. Chau Dang (110)
  6. Maura Dickler (102)

More People

Years
  1. 2021 (2)
  2. 2020 (5)
  3. 2019 (9)
  4. 2018 (19)
  5. 2017 (43)
  6. 2016 (65)

More Years

Publications
  1. Journal of Clinical Oncology (244)
  2. Cancer Research (108)
  3. Breast Cancer Research and Treatment (77)
  4. Clinical Cancer Research (33)
  5. Cancer (30)
  6. Annals of Oncology (29)

More Publications

Publishers
  1. American Society of Clinical Oncology (247)
  2. American Association for Cancer Research (163)
  3. Springer (100)
  4. Elsevier Inc. (83)
  5. Wiley Blackwell (44)
  6. Oxford University Press (42)

More Publishers

Results (898)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)
    Meeting Abstract

    Ma, C. X.; Suman, V.; Leitch, A. M.; Sanati, S.; Vij, K.; Unzeitig, G. W.; Hoog, J.; Watson, M.; Hahn, O.; Guenther, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE trial analysis (Alliance A011106)
    Meeting Abstract

    Ellis, M. J.; Suman, V.; Leitch, A. M.; Sanati, S.; Vij, K.; Unzeitig, G. W.; Hoog, J.; Watson, M.; Hahn, O.; Guenther, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
    Journal Article

    Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
    Nature Cancer (2020)

    Fulltext@MSK | Save
  • Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer
    Journal Article

    Fernandez-Martinez, A.; Krop, I. E.; Hillman, D. W.; Polley, M. Y.; Parker, J. S.; Huebner, L.; Hoadley, K. A.; Shepherd, J.; Tolaney, S.; Lynn Henry, N.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or Ill estrogen receptor-positive HER2-negative breast cancer (ER+HER2-BC) in postmenopausal (PM) women: Alliance A011106
    Meeting Abstract

    Ma, C. X.; Suman, V. J.; Leitch, A. M.; Sanati, S.; Vij, K. R.; Unzeitig, G. W.; Hoog, J.; Watson, M.; Hahn, O. M.; Guenther, J. M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • First-in-human trial of epichaperome-targeted PET in patients with cancer
    Journal Article

    Dunphy, M. P. S.; Pressl, C.; Pillarsetty, N.; Grkovski, M.; Modi, S.; Jhaveri, K.; Norton, L.; Beattie, B. J.; Zanzonico, P. B.; Zatorska, D.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Personalized management of chemotherapy-induced peripheral neuropathy based on a patient reported outcome: CALGB 40502 (Alliance)
    Journal Article

    Sharma, M. R.; Mehrotra, S.; Gray, E.; Wu, K.; Barry, W. T.; Hudis, C.; Winer, E. P.; Lyss, A. P.; Toppmeyer, D. L.; Moreno-Aspitia, A.; more...
    Journal of Clinical Pharmacology (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of gemcitabine with trastuzumab and pertuzumab after prior pertuzumab-based therapy among patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A phase 2 clinical trial
    Journal Article

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Fornier, M. N.; Goldfarb, S.; Jhaveri, K.; more...
    JAMA Network Open (2019)

    Fulltext@MSK | Save
  • Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer
    Journal Article

    Tolaney, S. M.; Guo, H.; Pernas, S.; Barry, W. T.; Dillon, D. A.; Ritterhouse, L.; Schneider, B. P.; Shen, F.; Fuhrman, K.; Baltay, M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Copper-64 trastuzumab PET imaging: A reproducibility study
    Journal Article

    Carrasquillo, J. A.; Morris, P. G.; Humm, J. L.; Smith-Jones, P. M.; Beylergil, V.; Akhurst, T.; O'Donoghue, J. A.; Ruan, S.; Modi, S.; Hudis, C. A.; more...
    Quarterly Journal of Nuclear Medicine and Molecular Imaging (2019)

    Fulltext@MSK | Save